Abbonarsi

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE - 04/09/11

Doi : 10.1016/S0889-8561(05)70142-9 
Trudy Small, MD *

Riassunto

Severe combined immunodeficiency disease (SCID) refers to a heterogeneous group of rare (1/100,000 live births), lethal, congenital disorders that result in the inability of T cells to respond to mitogens, alloantigens, and specific antigens and B cells to produce specific antibodies.1 Before the early 1990s, patients with this disorder were characterized primarily by the phenotype and function of their circulating lymphocytes, mode of inheritance, and presence or absence of enzyme deficiencies known to be associated with SCID, such as adenosine deaminase. In this original classification, three main types of SCID were described2 and include the following: (1) classical SCID, characterized by T and B lymphopenia, with or without natural killer (NK) cells, and agammaglobulinemia, (2) the more common SCID with B lymphocytes, and (3) SCID secondary to adenosine deaminase (ADA) deficiency, which may present with either of the preceding lymphoid phenotypes.3, 4 Less often, children with SCID present with Omenn's syndrome,5 in which affected infants have scaling erythroderma, leukocytosis, eosinophilia, hepatosplenomegaly, and lymphadenopathy with replacement of nodal architecture by Langerhans and reticulum cells,6 reticular dysgenesis,7 in which SCID is associated with severe neutropenia and often bilateral sensorineural deafness,8 or SCID with short-limbed dwarfism and ectodermal dysplasia.9 Multiple variants of SCID have been described in which patients have nonfunctional T cells that demonstrate capping defects,10 lack CD711 or possess abnormal CD3 subunit expression,12 or have CD8 deficiency with nonfunctional CD4+ cells.13, 14 Despite this phenotypic heterogeneity, the distribution of SCID phenotypes reported in four separate studies performed in Europe and the United States was surprisingly similar.15, 16, 17, 18 Approximately 40% of patients presented as SCID with B cells, 25% as classical SCIDs (BT), 15% with ADA deficiency, 10% as SCIDs with nonfunctional T cells, and 2% to 3% with reticular dysgenesis. Inheritance of these disorders are either autosomal recessive (ADA deficiency,4, 19 short-limbed dwarfism,9 Omenn's syndrome,5 capping defects,10 CD8 deficiency,13, 14 or as either an X-linked or autosomal recessive disorder (classical SCID, SCID with B cells, reticular dysgenesis).14, 20

Although first trimester diagnosis of adenosine deaminase deficiency has been possible for many years by measurement of enzyme activity in cultured amniocytes or chorionic villi samples,21 children with ADA+ SCID, until recently, required fetal blood sampling to ascertain the presence or absence of T cells.22 The elucidation of many of the genetic mutations which give rise to SCID, such as X-linked SCID (IL-2R gamma chain),23, 24, 25 autosomal recessive SCID with B cells (JAK-3),26, 27 classic SCID, Omenn's syndrome28, 29, 30, 31 (recombinase defects (RAG-1, RAG-2), and CD8 deficiency with nonfunctional T-cells (ZAP-70),32, 33, 34 has increased the proportion of infants who can be diagnosed by amniocentesis or chorionic villus sampling (CVS).35, 36 Better prenatal diagnosis, earlier postnatal diagnosis, because of heightened awareness of immunodeficiency disorders resulting from the AIDS epidemic, in conjunction with advances in anti-microbial therapy, have reduced the number of children presenting to bone marrow transplant (BMT) with a life-threatening infection.

Successful correction of SCID by BMT was first reported by Gatti et al using bone marrow derived from an HLA-matched sibling.37 Since that report, over 500 curative transplants for this disorder have been performed,38 the majority using T-cell–depleted haploidentical parental bone marrow. Within the last 5 years, advances in unrelated bone marrow39 and cord blood transplantation40 and successes with in utero stem cell transplants41 have expanded the options available to infants with SCID, particularly those lacking an HLA-matched sibling. In this article, the results and continued controversies of stem cell transplantation for SCID are reviewed.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Address reprint requests to Trudy Small, MD, Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room H-1406, New York, NY 10021, e-mail: Small_Trudy_N/mskcc_PED@mskmail.mskcc.org


© 2000  W. B. Saunders Company. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 20 - N° 1

P. 207-220 - febbraio 2000 Ritorno al numero
Articolo precedente Articolo precedente
  • ATAXIA-TELANGIECTASIA : A Primary Immunodeficiency Revisited
  • José R. Regueiro, Oscar Porras, Martin Lavin, Richard A. Gatti
| Articolo seguente Articolo seguente
  • GENE THERAPY FOR T-CELL IMMUNODEFICIENCIES
  • Donald B. Kohn, Kenneth I. Weinberg, Robertson Parkman

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.